Background . Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction. Objectives . Objectives are to evaluate the efficacy and safety of liraglutide 3.0 mg in patients with overweight and obesity irrespective of diabetic status. Methods . We conducted an electronic databa…